Who is sponsoring NCT03681912?

NCT03681912 is sponsored by Florida State University.

What drugs are being tested in NCT03681912?

Interventions in NCT03681912: Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS), Randomized Guided Development of COPs with an internal facilitator after one year of implementation., CoP development without internal facilitation..

What condition does NCT03681912 study?

NCT03681912 studies HIV Infections, Adolescent Development, Care Eliciting Behavior, Patient Non-Compliance, Patient Refusal of Treatment.

Is NCT03681912 still recruiting?

NCT03681912 is currently completed. Last updated 15 January 2025.

Are results published for NCT03681912?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-01-15 · How we verify

NCT03681912: TMI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tailored Motivational Interviewing Implementation-Effectiveness Trial in Multidisciplinary Adolescent HIV Care Settings

Completed Results posted Last updated 15 January 2025

What this trial tests

trial testing Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) in HIV Infections in 188 participants. Completed in 31 December 2021.

Timeline

28 August 2017

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Florida State University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	188
Start date	28 August 2017
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across United States

Drugs / interventions tested

Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS)
Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
CoP development without internal facilitation.

Conditions studied

HIV Infections — all drugs for HIV Infections →
Adolescent Development — all drugs for Adolescent Development →
Care Eliciting Behavior — all drugs for Care Eliciting Behavior →
Patient Non-Compliance — all drugs for Patient Non-Compliance →

Sponsor

Florida State University

Who can join

Adults 18 to 65, any sex, with HIV Infections or Adolescent Development. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Raw Average: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) Primary · Every three months over fifteen months

Providers will complete a 15-minute standard patient role-play at each point during baseline, implementation and sustainment. The Research Assistant (RA) will code these interactions on the 12-item MI CRS and reliability will continue to be monitored with one coding per month co-coded by Dr. Naar. These reports will be cumulatively reported and collected quarterly. Each item on the CRS has a score of 1 (lowest) to 4 (highest). The 12 scores are added and averaged for a score that reflects competency: \<2.0=Beginner. \>=2.0 to \<2.6. \>=2.6 to \<3.3=Intermediate. \>=3.3=Advanced. The outcomes

Implementation Phase

Group	Value	95% CI
Block 1 Site 7 - CoP Alone	2.72	± 0.45
Block 1 Site 10 - CoP Facilitated	2.50	± 0.46
Block 2 Site 3 - CoP Facilitated	1.99	± 0.34
Block 2 Site 8 - CoP Alone	2.32	± 0.51
Block 3 Site 1 - CoP Facilitated	2.47	± 0.53
Block 3 Site 11 - CoP Alone	2.91	± 0.37
Block 4 Site 2 - CoP Facilitated	2.62	± 0.50
Block 4 Site 12 - CoP Alone	2.39	± 0.43
Block 5 Site 6 - CoP Alone	2.63	± 0.49
Block 5 Site 13 - CoP Facilitated	2.66	± 0.48

Sustainment Phase

Group	Value	95% CI
Block 1 Site 7 - CoP Alone	2.78	± 0.43
Block 1 Site 10 - CoP Facilitated	2.59	± 0.26
Block 2 Site 3 - CoP Facilitated	2.19	± 0.37
Block 2 Site 8 - CoP Alone	2.19	± 0.26
Block 3 Site 1 - CoP Facilitated	2.38	± 0.56
Block 3 Site 11 - CoP Alone	2.82	± 0.43
Block 4 Site 2 - CoP Facilitated	2.73	± 0.51
Block 4 Site 12 - CoP Alone	2.41	± 0.48
Block 5 Site 6 - CoP Alone	2.76	± 0.61
Block 5 Site 13 - CoP Facilitated	2.65	± 0.45

Change in Individual Patients' Records Report Related to HIV Viral Load Secondary · 12 months prior to start; The end of the 12 month intervention, and 6 months after end of implementation interview

Record/chart abstraction conducted for patients in care at the site for * The 12 months prior to the start of implementation * The 12 months during implementation; and * The 6 months after the end of the implementation intervention. These data include viral load

Baseline Phase - 12 months prior to the start of implementation

Group	Value	95% CI
Block 1 Site 7	1.88	± 0.80
Block 1 Site 10	2.43	± 1.04
Block 2 Site 3	2.29	± 1.05
Block 2 Site 8	2.28	± 1.12
Block 3 Site 1	2.30	± 1.17
Block 3 Site 11	2.20	± 0.99
Block 4 Site 2	2.36	± 1.25
Block 4 Site 12	2.35	± 1.20
Block 5 Site 6	1.92	± 1.70
Block 5 Site 13	1.11	± 2.89

Implementation Phase - 12 months during implementation

Group	Value	95% CI
Block 1 Site 7	1.85	± 0.86
Block 1 Site 10	1.81	± 0.61
Block 2 Site 3	2.12	± 1.25
Block 2 Site 8	1.89	± 0.97
Block 3 Site 1	2.00	± 1.07
Block 3 Site 11	2.07	± 1.09
Block 4 Site 2	2.12	± 1.27
Block 4 Site 12	2.10	± 1.21
Block 5 Site 6	1.78	± 1.49
Block 5 Site 13	2.38	± 1.25

Sustainment Phase - 6 months after the end of the implementation

Group	Value	95% CI
Block 1 Site 7	1.88	± 0.83
Block 1 Site 10	1.80	± 0.59
Block 2 Site 3	2.31	± 1.23
Block 2 Site 8	2.00	± 1.10
Block 3 Site 1	1.98	± 1.08
Block 3 Site 11	1.90	± 0.77
Block 4 Site 2	2.22	± 1.19
Block 4 Site 12	1.76	± 0.87
Block 5 Site 6	1.79	± 0.77
Block 5 Site 13	2.17	± 1.15

Sponsor's own description

The goal of this study is to test a multi-faceted Tailored Motivational Interviewing Implementation intervention (TMI), based on the Dynamic Adaptation Process (DAP) to scale up an Evidence-based Practice (EBP) in multidisciplinary adolescent HIV care settings while balancing flexibility and fidelity. A mixed-methods design will be used, in which the dominant method is quantitative (a dynamic wait-listed design; DWLD) to determine the impact of TMI on the integration of MI with fidelity in 10 adolescent HIV clinics with an average of 15 providers and 100 patients each.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Testing a Motivational Interviewing Implementation Intervention in Adolescent HIV Clinics: Protocol for a Type 3, Hybrid Implementation-Effectiveness Trial.
Naar S, MacDonell K, Chapman JE, Todd L, et al · · 2019 · cited 21× · PMID 31237839 · DOI 10.2196/11200
Adapting the self-assessment of contextual fit scale for implementation of evidence-based practices in adolescent HIV settings.
Coyle K, Carcone AI, Butame S, Pooler-Burgess M, et al · · 2022 · cited 4× · PMID 36273221 · DOI 10.1186/s43058-022-00349-4
Cost of implementing tailored motivational interviewing training in youth HIV clinics.
MacDonell KK, Simpson KN, Todd L, Hall AL, et al · · 2026 · PMID 42063152 · DOI 10.1186/s12913-026-14622-y

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other Florida State University trials

Trials by the same sponsor.

NCT06127914 — Learning Early Infant Feeding Cues · NA · not yet recruiting
NCT06015581 — Scaling Up Implementation Strategies to Improve the DIAGNOSE and PREVENT Pillars for Young MSM in Florida · NA · not yet recruiting
NCT07467473 — Causal Role of Rostromedial Prefrontal Cortex for Positive Savoring in Depression · NA · enrolling by invitation
NCT07221448 — Sodium vs Potassium Education to Improve Vascular Health · NA · recruiting
NCT07415941 — MBM and taVNS for Low Back Pain and Depressive Symptoms · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03681912 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Florida State University
Last refreshed: 15 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03681912.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing